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Abstract
Background: Chondroitin sulfate proteoglycans are major inhibitory molecules for neural plasticity under both
physiological and pathological conditions. The chondroitin sulfate degrading enzyme chondroitinase ABC promotes
functional recovery after spinal cord injury, and restores experience-dependent plasticity, such as ocular dominance
plasticity and fear erasure plasticity, in adult rodents. These data suggest that the sugar chain in a proteoglycan
moiety is essential for the inhibitory activity of proteoglycans. However, the significance of the core protein has not
been studied extensively. Furthermore, considering that chondroitinase ABC is derived from bacteria, a mammalian
endogenous enzyme which can inactivate the proteoglycans’ activity is desirable for clinical use.
Methods: The degradation activity of ADAMTS-4 was estimated for the core proteins of chondroitin sulfate
proteoglycans, that is, brevican, neurocan and phosphacan. To evaluate the biological significance of ADMATS-4
activity, an in vitro neurite growth assay and an in vivo neuronal injury model, spinal cord contusion injury, were
employed.
Results: ADAMTS-4 digested proteoglycans, and reversed their inhibition of neurite outgrowth. Local
administration of ADAMTS-4 significantly promoted motor function recovery after spinal cord injury. Supporting
these findings, the ADAMTS-4-treated spinal cord exhibited enhanced axonal regeneration/sprouting after spinal
cord injury.
Conclusions: Our data suggest that the core protein in a proteoglycan moiety is also important for the inhibition
of neural plasticity, and provides a potentially safer tool for the treatment of neuronal injuries.
Keywords: ADAMTS-4, Spinal cord injury, Extracellular matrix, Chondroitin sulfate proteoglycan, Keratan sulfate pro-
teoglycan, Rat
Background
Following neuronal injury, damaged axons may regener-
ate or spared axons may sprout, resulting in synaptic
reconnection and reconstruction. However, such plasti-
city after neuronal injury does not occur extensively in
the adult mammalian central nervous system (CNS).
This is due to a lack of growth-promoting factors, the
poor intrinsic regenerative capacity of CNS neurons and
the emergence of inhibitory factors after injury [1-7].
Chondroitin sulfate (CS) proteoglycans (CSPGs) are
glial scar-associated inhibitors. The inhibitory function
of CSPGs on axonal outgrowth is primarily due to their
covalently attached CS-glycosaminoglycans. For exam-
ple, the CS-degrading enzyme chondroitinase ABC (C-
ABC) enhances axonal regeneration/sprouting after CNS
injury and consequently promotes functional recovery
[8,9]. Supporting these data,C S P G ss t r o n g l yi n h i b i t
neurite outgrowth in vitro, and C-ABC reverses it [7]. In
addition to CSPGs, we found that keratan sulfate pro-
teoglycans (KSPGs) inhibit axonal regeneration/sprout-
ing after injury [10,11]. Thus, in vivo neurite outgrowth
after a cortical stab wound is enhanced in mice deficient
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exhibit better motor function recovery after spinal cord
injury (SCI) [11]. Furthermore, we found that proteogly-
cans including both CSPGs and KSPGs inhibit neurite
outgrowth in vitro, and the KS-degrading enzyme kera-
tanase II reverses this inhibition [11]. These data collec-
tively suggest that glycosaminoglycans (GAGs), such as
CS and KS, in a proteoglycan moiety play a central role
in proteoglycan-mediated inhibition of neural plasticity
after injury.
As both C-ABC and keratanase II are of bacterial ori-
gin, repeated use of these enzymes may give rise to
adverse effects, such as undesirable generation of antibo-
dies, making their application to therapy limited. There-
fore, it would be ideal if we could use an endogenous
mammalian enzyme that inactivates the proteoglycans’
inhibitory function. However, a fundamental question
must be answered before using a mammalian enzyme
for this purpose. Namely, since proteoglycan is com-
posed of a core protein and GAGs, it should be deter-
mined whether the core protein, in addition to the
GAGs, in the proteoglycan moiety is essential for the
proteoglycan-mediated inhibition.
Based on the above background, we investigated the
effects of a proteoglycan-degrading enzyme, ADAMTS-4
(a disintegrin and metalloproteinase with thrombospon-
din motifs-4; also designated aggrecanase 1, which
stands for an enzyme degrading aggrecan, a common
CS/KSPG in the brain and cartilage), on neural plasticity
after SCI in this study. As ADAMTS-4 is known to
degrade the core protein of some CSPGs, we may deter-
mine the importance of the core protein on axonal
regeneration/sprouting. Here, we demonstrate that
ADAMTS-4 reverses the proteoglycan-mediated inhibi-
tion of neurite outgrowth in vitro, and promotes func-
tional recovery after SCI.
Methods
Spinal cord surgery
Adult female Sprague-Dawley rats weighing 200 to 230
g were used in this study. The animals were anesthe-
tized by intraperitoneal injection of ketamine (100 mg/
kg) and xylazine (10 mg/kg). After Th10 laminectomy,
we exposed the dura mater and induced injury using a
force of 200 kydn with a commercially available spinal
cord injury device (Infinite Horizon Impactor; Precision
Systems & Instrumentation, Lexington, KY, US). Imme-
diately after the spinal cord contusion, we performed a
Th11 partial laminectomy and inserted a thin silicone
tube with an osmotic mini-pump into the subarachnoid
cavity under a surgical microscope. The osmotic mini-
pump (Alzet pump model 2002 (Durect Corporation.,
Cupertino, CA, US): 200 μls o l u t i o n ,0 . 5μl/hour, 14-d
delivery) was filled with recombinant ADAMTS-4 (100
nM) (R&D Systems, Minneapolis, MN, US), C-ABC
(0.05 units/200 μl) (Seikagaku Corporation, Tokyo,
Japan) or PBS (as a vehicle control). The tube was
sutured to the spinous process to anchor it in place and
the minipump was placed under the skin on the ani-
mal’s back. Afterward, the muscles and skin were closed
in layers. The bladder was compressed by manual
abdominal pressure twice a day until bladder function
was restored. Food was provided on the cage floor, and
the rats had no difficulty reaching their water bottles.
All animals were given antibiotics in their drinking
water (1.0 ml Bactramin (Roche, Basel, Switzerland) in
500 ml acidified water) for two weeks after SCI. All ani-
mals were treated and cared for in accordance with the
Nagoya University Graduate School of Medicine guide-
lines pertaining to the treatment of experimental
animals.
Western blot analysis
To determine the ADAMTS-4 expression in the injured
spinal cord of the rats, the diffusion of His-tagged
A D A M T S - 4i n f u s e di n t ot h ei n j u r e ds p i n a lc o r dt i s s u e
and the degradation of brevican and neurocan by recom-
binant ADAMTS-4 enzyme, tissue extracts were analyzed
by SDS-PAGE/Western blot with anti-ADAMTS-4, anti-
His-Tag, anti-brevican, and anti-neurocan antibodies.
Samples of the supernatant fraction were collected after
centrifuging at 10000 g for 15 minutes and were sepa-
rated by electrophoresis on 5% SDS-PAGE. Proteins were
then blotted onto nitrocellulose membranes. Blots were
blocked with 5% fat-free dry milk in PBS for 60 minutes
and incubated overnight at 4°C with the primary anti-
body (anti-ADAMTS-4(1000 × dilution; Santa Cruz Bio-
technology, Santa Cruz, CA, US), anti-His-Tag (1000 ×
dilution; MBL, Nagoya, Japan), anti-brevican (1000 ×
dilution; BD Biosciences, San Jose, CA, US), and anti-
neurocan (1000 × dilution; clone 1G2, Seikagaku Cor-
poration) ) in PBS containing 0.3% Triton X-100. They
were washed and then were incubated with a second
antibody (horseradish peroxidase-conjugated anti-goat
and anti-mouse immunoglobulin G (IgG; 5000 × dilution;
Jackson ImmunoResearch, West Grove, PA, US)) in PBS
containing 0.3% Triton X-100 at room temperature for
60 minutes. Anti-b-actin antibody (1000 × dilution;
Sigma, St. Louis, MO, US) was also used as indicated.
Bound antibodies were visualized with an ECL and ECL-
plus Western blotting detection kit (GE Healthcare,
Buckinghamshire, UK).
Fluorescent assay of ADAMTS-4 activity
To measure ADAMTS-4 activity in the rat spinal cord,
we used the SensoLyte
® 520 Aggrecanase-1 Fluoro-
metric Assay Kit (AnaSpec, Fremont, CA, US). A tissue
sample from the rat spinal cord was diluted in 50 μlo f
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Tokyo, Japan). Then, 50 μl of aggrecanase substrate
solution was added into each well and incubated for 60
minutes at room temperature. Fluorescence was mea-
sured at 30°C using a POWERSCAN 4 (DS Pharma Bio-
medical, Osaka, Japan) equipped with a 490-nm
excitation filter and a 520-nm emission filter.
To evaluate the thermo-stability of ADAMTS-4, the
enzyme (10 nM) was incubated in vitro at 37°C. After
two weeks incubation, the enzyme activity was
measured.
Cell culture
Sprague Dawley rats were killed on postnatal days 7 to
9, and the cerebella were collected. The meninges were
carefully removed with fine forceps and the remaining
tissues were minced and digested using a Papain Disso-
ciation System (Worthington Biochemical, Lakewood,
NJ, US). Dissociated cells were applied to a 35/60% two-
step Percoll gradient and centrifuged at 3000 g for 15
minutes. Cerebellar granule neurons at the interface
were collected. Cells were suspended in neurobasal
medium (Invitrogen, Carlsbad, CA, US) supplemented
with 2% B27 (Invitrogen), 2 mM glutamine, an addi-
tional 20 mM KCl, 50 U/ml penicillin, and 50 μg/ml
streptomycin.
Primary cultures of cerebral cortical astrocytes were
prepared from newborn Sprague-Dawley rats as pre-
viously described [12,13]. Briefly, forebrains were
removed aseptically from the skulls, the meninges were
excised carefully under a dissecting microscope and the
cortices were isolated. The small tissues obtained by
mincing the cortices were cultured in flasks in DMEM
containing 10% fetal bovine serum (FBS), then incubated
at 37°C in a humidified atmosphere containing 5% CO2.
The culture medium was renewed every three to five
days. Experiments were performed on confluent 30-day-
old cultures. More than 95% of the obtained cells were
glial fibrillary acidic protein (GFAP)-positive. Astrocytes
were plated at a density of 5 × 10
5 cells per 3.5-cm dish.
Microglia-enriched cultures were obtained using the
method of Giulian et al. [14]. Briefly, small pieces of tis-
sues were obtained by mincing the cortices as described
above for the astrocyte primary culture and then were
cultured in flasks in Mi-medium (DMEM, 10% FBS,
0.2% glucose and insulin 5 μg/ml). The mixed glial cul-
ture grown for 21 days was subjected to shaking at 200
rpm on a gyratory shaker for 30 minutes. The detached
cells (mainly microglia) were reseeded in fresh culture
flasks, and after two hours any contaminating oligoden-
drocyte progenitors were detached with Tris-buffered
saline containing 1 mM ethylenediaminetetraacetic acid
(EDTA). This procedure routinely provides a firmly
attached homogeneous population of microglia.
M i c r o g l i aw e r ec u l t u r e di nD M E Mc o n t a i n i n g1 0 %F B S .
More than 95% of the obtained cells were found to be
Iba1-positive. Microglial cells were plated at a density of
1×1 0
5 cells per 3.5-cm dish.
RNA extraction and reverse transcription-polymerase
chain reaction (RT-PCR)
The total RNA of the cells was isolated using an RNeasy
Tissue Mini Kit (Qiagen, Valencia, CA, US) according
to the manufacturer’s instructions. One microgram of
purified total RNA was transcribed using SuperScript III
First-Strand Synthesis Super Mix (Invitrogen). The
cDNA products were used for the polymerase chain
reactions (PCRs), which were performed using a Veriti
96-well Thermal Cycler (Applied Biosystems, Foster
City, CA, US) according to the following protocol: 35
cycles of denaturing at 94°C for 30 seconds, annealing at
58°C for 30 seconds, and elongation at 72°C for 60 sec-
onds. The rat ADAMTS-4 primers were 5’-ctacaaccacc-
gaaccgac-3’ (forward) and 5’-tgccagccaccagaactt-3’
(reverse). The rat glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) primers were 5’-tatgactctacccacggcaag-
3’ (forward) and 5’-tgcattgctgacaatcttgag-3’ (reverse).
PG degradation assay by ADAMTS-4
Whole brains were isolated from adult female Sprague-
Dawley rats. Tissues were homogenized in PBS contain-
ing 10 mM N-ethylmaleimide and protease inhibitor
mixtures (Nacalai Tesque, Kyoto, Japan) using a
Dounce-type homogenizer. Homogenates were centri-
fuged at 24000 g for 30 minutes and supernatants were
applied to diethylaminoethyl (DEAE) Sepharose (GE
Healthcare). Samples were washed three times with
wash buffer (50 mM Tris-HCl, pH 7.5, 2 M urea, 0.25
M NaCl, 20 mM EDTA, 0.2 mM PMSF, 1 mM N-ethyl-
maleimide), and the proteoglycans were eluted with 2 M
NaCl. The eluent was concentrated using a size-exclu-
sion spin column (molecular weight cutoff, 100 kDa),
and the protein concentration was determined using a
Micro BCA Protein Assay kit (Thermo Fisher Scientific,
Waltham, MA, US). Purified PG samples were incubated
with 1 μM recombinant human ADAMTS-4 and
ADAMTS-13 (R&D Systems) (diluted in 10 mM Tris-
HCl, 0.15 M NaCl, and 10 mM CaCl2) for 3 hours at
37°C. Controls included samples with ADAMTS-4 that
were inactivated by heating at 95°C for 30 minutes.
After a 3 hour incubation period, 1 M dithiothreitol
(DTT) SDS-PAGE sample buffer was added to the sam-
ples, and then the samples were heated at 95°C for 5
minutes and subjected to SDS-PAGE and Western blot-
ting. Membranes were probed with mouse anti-brevican,
anti-neurocan and anti-phosphacan (1000 × dilution),
and the primary antibody was detected with anti-mouse,
anti-rabbit IgG conjugated to horseradish peroxidase.
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blotting detection kit.
Neurite outgrowth assays
Sprague Dawley rats were killed on postnatal days 7 to
9, and the cerebella were collected. The meninges were
carefully removed with fine forceps and the remaining
tissues were minced and digested using a Papain Disso-
ciation System. Dissociated cells were applied to a 35/
60% two-step Percoll gradient and centrifuged at 3000 g
for 15 minutes. Cerebellar granule neurons at the inter-
face were collected. Cells were suspended in neurobasal
medium supplemented with 2% B27, 2 mM glutamine,
an additional 20 mM KCl, 50 U/ml penicillin, and 50
μg/ml streptomycin. Four-well chamber slides (NUNC,
Roskilde, Denmark) were coated with 20 μg/ml poly-L-
lysine (PLL; Sigma) and left overnight at 4°C and then
were coated with chick brain proteoglycans (Millipore
Bioscience Research Reagents, Temecula, CA, US) and
left for 4 hours at 37°C. If indicated, proteoglycans were
treated with 10 nM ADAMTS-4 or 200 mU/ml C-ABC
in PBS at 37°C. Cerebellar granule neurons were seeded
onto four-well chamber slides at 2.0 × 10
5 per well.
Twenty-four hours after seeding, the neurons were fixed
with 4% paraformaldehyde/PBS and stained with anti-
neuron-specific b-tubulin (Covance, Princeton, NJ, US)
to visualize neurites. Neurite lengths were measured
from at least 100 neurons that had neurites longer than
twice the cell body diameter, per condition from dupli-
cate wells, and quantified as described previously [15].
The number of adherent cells was counted under 200 ×
magnification (six fields).
Behavioral test
The locomotor performance of animals was analyzed
using the Basso, Beattie and Bresnahan scale (BBB)
open-field score for eight weeks, since the BBB has been
shown to be a valid locomotor rating scale for rats. The
evaluations were made by two blind observers for all
analyzed groups. Briefly, the BBB is a twenty-one-point
scale that provides a gross indication of locomotor abil-
ity and determines the phases of locomotor recovery
and features of locomotion. The BBB score was deter-
mined for nine rats in each group.
Immunohistochemistry
Rats were perfused transcardially under deep ether
anesthesia with buffered 4% paraformaldehyde. The spinal
cords were removed, postfixed in 4% paraformaldehyde
overnight and cryoprotected in buffered 30% sucrose dur-
ing the subsequent night. Tissues were cut into 20 μm sec-
tions with a cryostat and mounted on glass slides. Sections
were blocked in PBS containing 3% BSA. Sections were
then incubated with 5-hydroxytryptamine (5-HT) antibody
(100 × dilution; Immunostar, Hudson, WI, US) in a block-
ing solution overnight at 4°C in PBS containing 3% BSA.
After rinsing in PBS, the sections were incubated with the
secondary antibody (100 × dilution; Alexa 488 conjugated
anti-rabbit antibody; Invitrogen) for 60 minutes at room
temperature. Subsequently, the sections were rinsed in
PBS, mounted with FluorSave (Calbiochem, San Diego,
CA), and examined by an Olympus model BX41 micro-
scope fitted with the appropriate filters.
Morphometry
The epicenter of a lesion was determined by hematoxylin
and eosin staining of several of the serial 20 μms e c t i o n s .
A l lt h ec r o s s - s e c t i o n a li m a ge analyses were performed
using spinal cord samples from positions 5 mm caudal to
the lesion site. Mean values for each animal were then
compared. Light intensity and thresholding values were
maintained at constant levels for all analyses by a compu-
ter-driven microscope stage (MetaMorph Offline version
6.3 r
2; Molecular Devices, Sunnyvale, CA, US). The
amounts of axonal outgrowth of the wound area were
assessed by counting signals visualized by staining with
anti-5-HT antibody, for 650 × 860 μm
2 counting frames
around a lesion. Statistical analyses were performed for
five rats for each experimental group.
Statistical analysis
Using SPSS (SPSS Inc., Chicago, IL, US), data for the
BBB score were analyzed by repeated measures analysis
of variance (ANOVA) with a post hoc Bonferroni test.
Data were statistically analyzed using an unpaired two-
tailed Student’s t-test for histological assessment for the
area of 5-HT-positive fiber. In all statistical analyses,
values of P < 0.05 were considered to indicate signifi-
cance. When gathering data for the statistical analyses,
the investigators were blinded to each group in all
procedures.
Results
ADAMTS-4 expression and activity in the injured spinal
cord of rats
The level of ADAMTS-4 protein was slightly increased
after SCI, as revealed by Western blot analysis of the
spinal cord lysate seven days after injury (Figure 1A).
ADAMTS-4 is known as a degrading enzyme for the
CS/KSPG aggrecan. To determine whether its expres-
sion after SCI was accompanied by an elevation of pro-
teolytic activity, an assay using fluorescent substrate was
employed. The spinal cord lysate seven days after injury
showed a significant elevation of the aggrecan-degrada-
tion activity of ADAMTS-4 (approximately 1.4 fold ver-
sus sham-operated rats) (Figure 1B).
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To determine which cells express ADAMTS-4 in the CNS,
we performed an RT-PCR analysis. Strong ADAMTS-4
expression was detected in primary cultured astrocytes
and microglia, but not in neurons (Figure 1C).
ADAMTS-4 degrades the endogenous CSPGs brevican,
neurocan and phosphacan
To explore the possibility that ADAMTS-4 has a wide
range of substrates, not limited to aggrecan, we further
examined its degradation activity on endogenous CSPGs
in the CNS. To this end, homogenates of rat brain were
applied to a DEAE column, and highly negatively-
charged species were eluted with 1 M NaCl. When tis-
sue extracts of the spinal cord were directly used for
Western blotting, many degradation products of proteo-
glycans were detected even without SCI (data not
shown). Therefore, to estimate the degradation activity
of ADAMTS-4, a gross purification of PGs with a DEAE
column was needed. Indeed this purification provided
PGs with over 100 kDa (Figure 2A-C, Control). The
grossly purified proteoglycans were incubated with
active or heat-inactivated human recombinant
ADAMTS-4 or ADAMTS-13 for 3 hours. ADAMTS-13
has a thrombospondin type I sequence repeat motif and
peptidase activity as ADAMTS-4 does, but shows dis-
tinct substrate specificity, that is, it specifically digests
von Willebrand factor and regulates blood coagulation.
Furthermore, we found that ADAMTS-13 expression
was upregulated after SCI of rats (Tauchi et al., unpub-
lished data). Therefore, we used ADAMTS-13 as a nega-
tive control. After incubation, the samples were
subjected to Western blot analysis to detect the levels of
brevican, neurocan and phosphacan. Incubation with
ADAMTS-4 resulted in cleavage of brevican (Figure 2A,
ADAMTS-4), which is consistent with a previous report
[16,17]. We also demonstrated that ADAMTS-4
degraded neurocan and phosphacan (Figure 2B, C,
ADAMTS-4). Proteolytic activity was attenuated when
ADAMTS-4 was heat-inactivated prior to incubation
with substrate (Figure 2A-C, Inactive ADAMTS-4). In
contrast, ADAMTS-13 as well as its heat-inactivated
form did not degrade these proteoglycans (Figure 2A-C,
ADAMTS-13 and Inactive ADAMTS-13). Consistent
with our data, there has been no report thus far that
ADAMTS-13 cleaves proteoglycans, although it effec-
tively cleaves von Willebrand factor [18].
ADAMTS-4 reverses proteoglycans’ inhibition of neurite
growth
We next examined the effects of ADAMTS-4 on proteo-
glycan-mediated inhibition of neurite outgrowth. To this
end, cerebellar granule neurons were primary cultured
on PLL or chick brain-derived PGs coated on PLL on a
tissue culture dish. PGs coated on the substratum strik-
ingly inhibited neurite outgrowth of primary neurons as
compared with the PLL control (Figure 3A, B, E). Nota-
bly, ADAMTS-4 blocked the PG-mediated inhibition
and this blocking effect was comparable to that of C-
ABC (Figure 3C-E).
ADAMTS-4 promotes motor function recovery after SCI
The data so far shown indicated that ADAMTS-4
degraded CSPGs, which are known to inhibit neuronal
axon regeneration after injury. However, the level of
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Figure 1 ADAMTS-4 expression and activity in the injured
spinal cord of rats. ADAMTS-4 in the spinal cord tissue lysates was
slightly increased after spinal cord injury compared with the sham-
operated rats (Western blot analysis) (A). The proteolytic activity of
ADAMTS-4 was significantly increased by about 1.4-fold in the rat
spinal cord after injury (B). Enzymatic activities of tissue extracts of
the spinal cord (1 cm around the lesion) were measured. *, P < 0.01.
ADAMTS-4 mRNA was mainly expressed by astrocytes and microglia,
but not neurons (C).
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enhanced after SCI, appeared to be insufficient to over-
come the inhibitory activity of CSPGs, because SCI
leads to serious functional disturbance. Therefore, we
next investigated whether exogenous ADAMTS-4 would
ameliorate SCI. The adult rat spinal cord was inflicted
with a force of 200 kdyn at the Th10 level. ADAMTS-4
or C-ABC was locally infused at the injury site using an
osmotic pump for two weeks. The motor function
recovery was then evaluated using the BBB score. As
shown in Figure 4A, ADAMTS-4 and C-ABC signifi-
cantly improved motor function after SCI, compared to
the vehicle group (P < 0.05, respectively: repeated mea-
sure ANOVA). Notably, the effects of ADAMTS-4 and
C-ABC were comparable (Figure 4A). Therefore, our
data demonstrated that exogenous ADAMTS-4 pro-
moted motor function recovery after SCI.
To evaluate the thermo-stability of ADAMTS-4, we
incubated ADAMTS-4 solution (10 nM) in vitro for two
weeks at 37°C. It retained about 70% activity of the
fresh ADAMTS-4 (Figure 4B). Furthermore, we exam-
ined the extent of ADAMTS-4 diffusion into the tissue
after osmotic pump infusion. As the infused ADAMTS-
4 was tagged with His, its molecular weight was 58 kDa.
The 58 kDa band was detected at the epicenter of
ADAMTS-4 treated rat on Western blot analysis (Figure
4C, arrow). A band slightly lower than 58 kDa also
appeared most strongly at the epicenter in ADAMTS-4
treated rats (Figure 4C, asterisk), suggesting that it
might represent a processed form of the infused
ADAMTS-4 although its enzymatic activity was
uncertain. In accordance with this result, brevican and
neurocan were degraded at the injury epicenter of
ADAMTS-4 treated rat (Figure 4C). These data collec-
tively suggest that exogenous ADAMTS-4 cleaved its
substrates around the infused area and, consequently,
contributed to the functional recovery after SCI.
ADAMTS-4 promotes axonal regeneration/sprouting
Regeneration/sprouting of the serotonergic descending
raphespinal tract may partly explain the reason for
motor function recovery after SCI in rodents [19]. We
stained tissues 5 mm distal to the lesion for 5-HT, since
serotonergic axons are 5-HT-positive. 5-HT-positive
fibers were more abundantly found in the ventral horn
of the gray matter in the ADAMTS-4-treated rats than
in the vehicle rats (5-HT-positive area: ADAMTS-4
treated rats, 971 ± 407 versus the vehicle rats, 278 ±
102; P < 0.05) (Figure 5A-D).
Discussion
Is the degradation of ECM components beneficial or
detrimental to the process of neuronal injuries?
The extracellular matrix (ECM) maintains the integrity
of the CNS both structurally and functionally. Matrix
metalloproteinases (MMPs) are upregulated after cere-
bral infarction and are implicated in stroke pathology
[20,21]. Indeed, an MMP inhibitor has been shown to
reduce infarct size [22]. MMPs facilitate degradation of
ECM proteins, including collagen and laminin, loosen
the blood-brain barrier and promote the infiltration of
inflammatory cells. In addition, ADAM-17 enhances
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Figure 2 Cleavage of CSPGs by ADAMTS-4. Cleavage of brevican (A), neurocan (B), and phosphacan (C) by human recombinant ADAMTS-4.
CSPGs were incubated with the indicated enzymes and their degradation was estimated by Western blot analysis as described under the
Methods. ADAMTS-4 degrades brevican, neurocan and phosphacan, whereas inactive ADAMTS-4, which had been heat-denatured, and
ADAMTS-13 do not degrade these CSPGs. CSPGs, chondroitin sulfate proteoglycans.
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Page 6 of 10shedding of tumor necrosis factor (TNF) after ischemia
[23] and an ADAM-17 antagonist reduces infarct size
after transient middle cerebral artery occlusion [24].
Taken together, these results indicate that ECM-degrad-
ing enzymes, that is, MMPs and ADAM-17, worsen the
functional disturbance after stroke by promoting decon-
struction of the blood-brain barrier and infiltration of
the inflammatory cells. In this context, an unsolved
question is whether ADAMTS-4 is beneficial or detri-
mental to the process of neuronal injuries, because
CSPGs are the major component of the CNS ECM, and
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Figure 3 ADAMTS-4 restores neurite outgrowth. P8 rat cerebellar
granular neurons were cultured on PLL (A) or PG extracted from
chick brains (B). ADAMTS-4 (C) and C-ABC (D) treatments restored
the neurite outgrowth. Scale bar, 200 μm. (E) The quantification of
A to D. Data represent the relative ratio of the average neurite
length ± SD comparing PLL. *, P < 0.01 (versus PG: repeated-
measures ANOVA). ANOVA, analysis of variance; C-ABC,
chondroitinase ABC; PG, proteoglycan; PLL, poly-L-lysine.
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Figure 4 BBB score and the diffusion of exogenous ADAMTS-4
after SCI. The graph of BBB score shows data from nine rats for
each group at each time point (A). Values are presented as the
means ± SEM. *, P < 0.05 (versus vehicle: repeated-measures
ANOVA). ADAMTS-4 retained enzymatic activity after two weeks
incubation at 37°C (B). Brevican and neurocan were regionally
degraded by ADAMTS-4 around the infused area of the spinal cord
(C). His-tagged recombinant ADAMTS-4 (58 kDa: arrow) was
detected at the epicenter of the injured spinal cord of the ADAMTS-
4 treated rat. ANOVA, analysis of variance; BBB, Basso, Beattie, and
Bresnahan; d, day; SCI, spinal cord injury; SEM, standard error of the
mean; w, week.
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Page 7 of 10ADAMTS-4 is the most potent enzyme to degrade core
proteins of CSPGs, which include brevican, aggrecan,
versican, neurocan and phosphacan [16,17,25-27]. This
report shows for the first time that ADAMTS-4 is bene-
ficial to the process of a neuronal injury, namely, SCI.
ADAMTS-4 as a potent therapeutic agent for neuronal
injuries
A characteristic of the CNS ECM is that it is rich in
CSPGs and hyaluronan [28]. CSPGs may play a role in
the maintenance of the correct hydrodynamics through
their negatively charged properties, but also may contri-
bute to the maintenance of neuronal networks by inhi-
biting synaptic plasticity [29-31]. Among CSPGs, the
lectican family members (brevican, aggrecan, versican
and neurocan) bind hyaluronan through their globular
N-terminus [32]. This aggregated complex of matrix
composes perineuronal nets, confers stability in neuro-
nal networks, and inhibits plasticity after injuries [33].
ADAMTS-1, -4, -5, -8 and -9 degrade aggrecan, the
most abundant CSPG in the cartilage and are implicated
in cartilage degradation [25,26,34]. ADAMTS-4 degrades
aggrecan, versican and brevican [16,17,25-27]. In addi-
tion to these findings, we showed here that neurocan
and phosphacan were also cleaved by ADAMTS-4. We
also found that ADAMTS-4 was upregulated in the
spinal cord after SCI. Finally, we demonstrated that exo-
genous ADAMTS-4 promoted functional recovery after
SCI. Notably, the effects of ADAMTS-4 and C-ABC on
functional recovery were comparable. Regarding the
function of exogenous ADAMTS-4, we cannot exclude
the possibility that exogenous ADAMTS-4 exerts neuro-
protection. However, we observed that ADAMTS-4 pro-
moted neurite outgrowth in vitro and axonal
regeneration/sprouting in vivo. Considering also an
increasing body of evidence that CSPGs work as a
potent inhibitor for neural plasticity as mentioned
above, it is most likely that exogenous ADAMTS-4
essentially promoted axonal regeneration/sprouting and
consequently neuronal network reconstruction. Unlike
the expressions of C-ABC and keratanase II, ADAMTS-
4e x p r e s s i o ni sf o u n di nm a m m a l sa n di sd e t e c t e di n
the spinal cord. Furthermore, human ADAMTS-4 is
available. Therefore, this enzyme could be used for
humans without concerns about adverse effects, such as
the generation of antibodies, and is a candidate thera-
peutic agent for neuronal injuries.
The importance of the core protein in the proteoglycan-
mediated inhibition of neural plasticity
The ADAMTSs are a group of proteases that are found
both in mammals and invertebrates. The ADAMTSs are
extracellular, multidomain enzymes whose known func-
tions include: 1) collagen processing, 2) cleavage of the
matrix proteoglycans, 3) inhibition of angiogenesis, and
4) blood coagulation homoeostasis [35]. It is known that
ADAMTS-1, -4 and -5 cleave substrates at specific Glu-
Xb o n d s[ 2 7 ] .T h u s ,t h et a r g e to fA D A M T S - 4i st h e
core protein in a proteoglycan moiety. We also targeted
the core protein by heat-inactivating or reducing/
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Figure 5 Immunofluorescence analysis after SCI. 5-HT staining of the ventral horn (A-C, 5 mm distal to the lesion) is shown for the ADAMTS-
4 treatment group (A and B) and vehicle group (C). Higher-magnification of the boxed area in A is shown in B. The arrows in B and C indicate
5-HT-positive fibers. Scale bars, 500 μm( A) and 50 μm( B and C). (D) The 5-HT-positive areas are summarized in the graph. Five rats are used for
each group at eight weeks after spinal cord injury. *, P < 0.05. Values are presented as the means ± SD. 5-HT, 5-hydroxytryptamine; SCI, spinal
cord injury.
Tauchi et al. Journal of Neuroinflammation 2012, 9:53
http://www.jneuroinflammation.com/content/9/1/53
Page 8 of 10alkylating and found that those proteoglycans lost their
inhibitory activity on neurite growth [36]. Taken
together, our data highlight the importance of the core
protein in the proteoglycan-mediated inhibition of
neural plasticity.
The biological significance of the upregulation of
ADAMTS-4
It has been reported that CSPGs, including brevican,
neurocan, phosphacan, versican and NG2, are upregu-
lated after CNS injuries [37-42]. These CSPGs are also
upregulated after SCI [43]. We demonstrated here that
ADAMTS-4 expression was also increased following
SCI. An increase in ADAMTS-4 expression has also
been reported in the ipsilateral cerebral hemisphere fol-
lowing transient middle cerebral artery occlusion in the
rat [44], suggesting that the upregulation of ADAMTS-4
may be a general phenomenon induced by neuronal
injuries.
We demonstrated that ADAMTS-4 could degrade bre-
vican, neurocan and phosphacan, and reversed the neur-
ite growth inhibition mediated by chick brain
proteoglycans. Moreover, local administration of
ADAMTS-4 promoted axonal regeneration/sprouting
and motor function recovery after SCI. On the other
hand, this finding also indicates that the level of endo-
genous expression of ADAMTS-4 is not sufficient to
confer plasticity and functional recovery after SCI. The
cleavage of CSPGs induced by neuronal injuries may be
achieved not only by ADAMTS-4 but also by MMPs,
which are also upregulated after neuronal injuries
[20,21,45]. However, MMPs also cleave other matrix
proteins, such as collagen and laminin, loosen the
blood-brain barrier, enhance the infiltration of inflam-
matory cells, and worsen pathology. An elevation of
inflammatory cytokines, for example, TNF-a,i nt u r n
enhances ADAMTS-4 expression [46]. Therefore, a
complex molecular and cellular network may be estab-
lished after neuronal injuries to regulate the balance
between the production and removal of inhibitory fac-
tors for neural plasticity.
In this context, it is of note that the expressions of
ADAMTS-1 and -4 are elevated in rats with kainite
induced CNS lesions [47]. ADAMTS-4, in particular, is
strikingly upregulated and its well-known substrate bre-
vican is cleaved where ADAMTS-4 is expressed. Thus,
the report by Yuan et al. clearly demonstrates that
ADAMTS-4 expressed in vivo is actually proteolytically
active in situ i nt h eC N S .O u rs t u d ya l s od e m o n s t r a t e d
that heat-inactivated ADAMTS-4 lost its activity pro-
moting neurite outgrowth against proteoglycans. Taken
together, these data support the idea that the proteolytic
activity of ADAMTS-4 is central for its contribution to
functional recovery after SCI. On the other hand, it has
also been reported that a proteolytically inactive point
mutant of ADAMTS-4 promotes neurite outgrowth
extension through the activation of ERK kinase [48].
Thus, this interesting phenomenon should also be taken
into consideration as a potential mechanism.
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